Growth & profitability
- Revenue has declined 0.1% per year over the past 4 years.
- Net income has grown slower than revenue (-18.0% vs -0.1% per year).
- Operating margin has contracted, at 2.9% in the latest year.
ZJYL Financials Jin Medical International Ltd.
5 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $21M | $1M | 29.2% | 2.9% | -$4M | — | $7M |
| 2024 | $24M | $4M | 40.4% | 15.5% | -$1M | — | $8M |
| 2023 | $20M | $3M | 34.2% | 14.5% | $3M | — | $7M |
| 2022 | $19M | $3M | 32.3% | 11.1% | $2M | — | $5M |
| 2021 | $21M | $3M | 30.6% | 12.7% | $6M | — | $4M |
Valuation over time
How the market has priced ZJYL against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-earnings ratio has fallen from 433.8× (Mar '23) to 319.3× (Jun '26).
- The price-to-sales ratio has fallen from 61.2× (Mar '23) to 18.4× (Jun '26).
P/E
P/S
Frequently asked questions
Is ZJYL growing its revenue and profit?
Over the past 4 years, Jin Medical International Ltd.'s revenue has declined 0.1% per year, and net income declined 18.0% per year. These are computed facts, not advice.
How much debt does ZJYL have?
As of FY2025, Jin Medical International Ltd. reported — of total debt against $7M of cash.
What is ZJYL's profit margin?
In FY2025, gross margin was 29.2%, operating margin 2.9%, and net margin 5.8%.
What is ZJYL's P/E ratio?
As of Jun '26, Jin Medical International Ltd. traded at a price-to-earnings ratio of about 319.3× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.